Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX

  • Erik van Dijk
  • , Erik van Werkhoven
  • , Rebecca Asher
  • , Jennifer K. Mooi
  • , David Espinoza
  • , Hendrik F. van Essen
  • , Harm van Tinteren
  • , Nicole C.T. van Grieken
  • , Cornelis J.A. Punt
  • , Niall C. Tebbutt
  • , Bauke Ylstra

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology

Agricultural and Biological Sciences

Neuroscience